H Tonouchi1, C Miki, K Tanaka, M Kusunoki. 1. Dept of Innovative Surgery, Mie University Medical School, Tsu, Japan. tonouchi@clin.medic.mie-u.ac.jp
Abstract
BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) has been shown to act as a chemokine in the recruitment of monocyte/macrophages during inflammation states. It acts as an important factor in the cytokine network, which regulates tumor proliferation, whereas the association between serum MCP-1 level and gastric cancer has not yet been clarified. METHODS: The serum concentration of MCP-1 in 76 gastric cancer patients and in 45 normal controls was determined using an immunoradiometric assay. The concentration of MCP-1 in the 47 cancer tissue samples was also determined. RESULTS: The serum concentration of MCP-1 in patients with advanced carcinoma was significantly lower than that in controls. The serum concentration of MCP-1 in patients with advanced carcinoma was significantly lower than that in patients with early carcinoma. The serum concentration of MCP-1 was associated with clinicopathological factors including lymph node metastasis, serosal invasion and histological differentiation of the tumor. In patients who underwent palliative surgery, the serum MCP-1 level significantly decreased postoperatively, whereas in patients who underwent curative surgery the serum MCP-1 level tended to increase. The 4-year survival rate in patients whose serum MCP-1 levels were lower than or equal to the median value was significantly lower than that in patients whose MCP-1 levels were higher than the median value. The tissue concentration of MCP-1 in the cancer tended to decrease in accordance with disease progression. CONCLUSIONS: The serum level of MCP-1 decreased in accord with disease progression, which reflects local consumption in gastric cancer. Serum MCP-1 may be a useful marker that reflects the host's local resistance to the tumor.
BACKGROUND:Monocyte chemoattractant protein-1 (MCP-1) has been shown to act as a chemokine in the recruitment of monocyte/macrophages during inflammation states. It acts as an important factor in the cytokine network, which regulates tumor proliferation, whereas the association between serum MCP-1 level and gastric cancer has not yet been clarified. METHODS: The serum concentration of MCP-1 in 76 gastric cancerpatients and in 45 normal controls was determined using an immunoradiometric assay. The concentration of MCP-1 in the 47 cancer tissue samples was also determined. RESULTS: The serum concentration of MCP-1 in patients with advanced carcinoma was significantly lower than that in controls. The serum concentration of MCP-1 in patients with advanced carcinoma was significantly lower than that in patients with early carcinoma. The serum concentration of MCP-1 was associated with clinicopathological factors including lymph node metastasis, serosal invasion and histological differentiation of the tumor. In patients who underwent palliative surgery, the serum MCP-1 level significantly decreased postoperatively, whereas in patients who underwent curative surgery the serum MCP-1 level tended to increase. The 4-year survival rate in patients whose serum MCP-1 levels were lower than or equal to the median value was significantly lower than that in patients whose MCP-1 levels were higher than the median value. The tissue concentration of MCP-1 in the cancer tended to decrease in accordance with disease progression. CONCLUSIONS: The serum level of MCP-1 decreased in accord with disease progression, which reflects local consumption in gastric cancer. Serum MCP-1 may be a useful marker that reflects the host's local resistance to the tumor.
Authors: Zvi Granot; Erik Henke; Elizabeth A Comen; Tari A King; Larry Norton; Robert Benezra Journal: Cancer Cell Date: 2011-09-13 Impact factor: 31.743
Authors: T Kantola; K Klintrup; J P Väyrynen; J Vornanen; R Bloigu; T Karhu; K-H Herzig; J Näpänkangas; J Mäkelä; T J Karttunen; A Tuomisto; M J Mäkinen Journal: Br J Cancer Date: 2012-10-11 Impact factor: 7.640
Authors: Andrzej Eljaszewicz; Małgorzata Wiese; Anna Helmin-Basa; Michal Jankowski; Lidia Gackowska; Izabela Kubiszewska; Wojciech Kaszewski; Jacek Michalkiewicz; Wojciech Zegarski Journal: Mediators Inflamm Date: 2013-03-17 Impact factor: 4.711